Annual FCF
-$17.59 M
+$11.10 M+38.69%
31 December 2023
Summary:
AcelRx Pharmaceuticals annual free cash flow is currently -$17.59 million, with the most recent change of +$11.10 million (+38.69%) on 31 December 2023. During the last 3 years, it has risen by +$14.24 million (+44.73%).ACRX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$3.95 M
-$989.00 K-33.41%
31 December 2023
Summary:
AcelRx Pharmaceuticals quarterly free cash flow is currently -$3.95 million, with the most recent change of -$989.00 thousand (-33.41%) on 31 December 2023.ACRX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$17.59 M
+$1.51 M+7.91%
31 December 2023
Summary:
AcelRx Pharmaceuticals TTM free cash flow is currently -$17.59 million, with the most recent change of +$1.51 million (+7.91%) on 31 December 2023.ACRX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACRX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +44.7% | +50.8% | +44.7% |
| 5 y5 years | +67.8% | +72.6% | +67.8% |
ACRX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | +366.1% | -116.8% | +395.3% |
AcelRx Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$17.59 M(-38.7%) | -$3.95 M(+33.4%) | -$17.59 M(-7.9%) |
| Sept 2023 | - | -$2.96 M(-44.5%) | -$19.10 M(-11.3%) |
| June 2023 | - | -$5.33 M(-0.3%) | -$21.54 M(-13.9%) |
| Mar 2023 | - | -$5.35 M(-2.0%) | -$25.02 M(-12.8%) |
| Dec 2022 | -$28.70 M(-9.8%) | -$5.46 M(+1.2%) | -$28.70 M(-8.2%) |
| Sept 2022 | - | -$5.40 M(-38.8%) | -$31.27 M(+4.2%) |
| June 2022 | - | -$8.81 M(-2.3%) | -$30.00 M(-3.6%) |
| Mar 2022 | - | -$9.02 M(+12.3%) | -$31.12 M(-2.2%) |
| Dec 2021 | -$31.83 M(-21.1%) | -$8.03 M(+94.6%) | -$31.83 M(+0.2%) |
| Sept 2021 | - | -$4.13 M(-58.5%) | -$31.75 M(-11.3%) |
| June 2021 | - | -$9.94 M(+2.1%) | -$35.81 M(+0.4%) |
| Mar 2021 | - | -$9.73 M(+22.3%) | -$35.66 M(-11.7%) |
| Dec 2020 | -$40.36 M(-26.1%) | -$7.96 M(-2.7%) | -$40.36 M(-13.8%) |
| Sept 2020 | - | -$8.18 M(-16.4%) | -$46.80 M(-9.2%) |
| June 2020 | - | -$9.79 M(-32.2%) | -$51.52 M(-6.6%) |
| Mar 2020 | - | -$14.44 M(+0.3%) | -$55.19 M(+1.0%) |
| Dec 2019 | -$54.65 M(+82.8%) | -$14.40 M(+11.6%) | -$54.65 M(+10.4%) |
| Sept 2019 | - | -$12.90 M(-4.1%) | -$49.49 M(+14.9%) |
| June 2019 | - | -$13.45 M(-3.2%) | -$43.07 M(+19.0%) |
| Mar 2019 | - | -$13.90 M(+50.5%) | -$36.21 M(+21.1%) |
| Dec 2018 | -$29.89 M(-7.1%) | -$9.24 M(+42.4%) | -$29.89 M(+9.7%) |
| Sept 2018 | - | -$6.49 M(-1.5%) | -$27.24 M(-3.0%) |
| June 2018 | - | -$6.59 M(-13.1%) | -$28.07 M(-11.4%) |
| Mar 2018 | - | -$7.58 M(+15.1%) | -$31.68 M(-1.5%) |
| Dec 2017 | -$32.17 M(-2.9%) | -$6.59 M(-10.0%) | -$32.17 M(-14.8%) |
| Sept 2017 | - | -$7.32 M(-28.2%) | -$37.74 M(+3.1%) |
| June 2017 | - | -$10.20 M(+26.3%) | -$36.61 M(+5.3%) |
| Mar 2017 | - | -$8.07 M(-33.6%) | -$34.77 M(+5.0%) |
| Dec 2016 | -$33.12 M | -$12.15 M(+96.5%) | -$33.12 M(+131.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2016 | - | -$6.19 M(-26.0%) | -$14.30 M(+3.2%) |
| June 2016 | - | -$8.36 M(+30.2%) | -$13.85 M(-16.4%) |
| Mar 2016 | - | -$6.42 M(-196.4%) | -$16.56 M(-22.6%) |
| Dec 2015 | -$21.41 M(-46.4%) | $6.66 M(-216.1%) | -$21.41 M(-43.3%) |
| Sept 2015 | - | -$5.74 M(-48.2%) | -$37.74 M(-6.6%) |
| June 2015 | - | -$11.07 M(-1.8%) | -$40.39 M(+1.1%) |
| Mar 2015 | - | -$11.27 M(+16.5%) | -$39.95 M(-0.0%) |
| Dec 2014 | -$39.96 M(+958.9%) | -$9.67 M(+15.3%) | -$39.96 M(+490.8%) |
| Sept 2014 | - | -$8.39 M(-21.1%) | -$6.76 M(+5.2%) |
| June 2014 | - | -$10.63 M(-5.7%) | -$6.43 M(+20.7%) |
| Mar 2014 | - | -$11.28 M(-147.9%) | -$5.33 M(+41.1%) |
| Dec 2013 | -$3.77 M(-85.1%) | $23.53 M(-392.2%) | -$3.77 M(-88.6%) |
| Sept 2013 | - | -$8.05 M(-15.5%) | -$33.20 M(+4.2%) |
| June 2013 | - | -$9.53 M(-2.0%) | -$31.87 M(+18.2%) |
| Mar 2013 | - | -$9.72 M(+64.8%) | -$26.97 M(+6.1%) |
| Dec 2012 | -$25.41 M(+46.8%) | -$5.90 M(-12.2%) | -$25.41 M(-1.3%) |
| Sept 2012 | - | -$6.72 M(+45.4%) | -$25.74 M(+3.7%) |
| June 2012 | - | -$4.62 M(-43.4%) | -$24.83 M(+3.2%) |
| Mar 2012 | - | -$8.16 M(+31.0%) | -$24.06 M(+39.0%) |
| Dec 2011 | -$17.31 M(+41.5%) | -$6.23 M(+7.3%) | -$17.31 M(+21.4%) |
| Sept 2011 | - | -$5.81 M(+50.7%) | -$14.26 M(+31.4%) |
| June 2011 | - | -$3.86 M(+174.1%) | -$10.85 M(+7.6%) |
| Mar 2011 | - | -$1.41 M(-55.8%) | -$10.08 M(-17.5%) |
| Dec 2010 | -$12.23 M(-37.4%) | -$3.18 M(+32.6%) | -$12.23 M(+35.2%) |
| Sept 2010 | - | -$2.40 M(-22.4%) | -$9.05 M(+36.1%) |
| June 2010 | - | -$3.09 M(-12.9%) | -$6.65 M(+87.1%) |
| Mar 2010 | - | -$3.55 M | -$3.55 M |
| Dec 2009 | -$19.53 M(+0.4%) | - | - |
| Dec 2008 | -$19.45 M | - | - |
FAQ
- What is AcelRx Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for AcelRx Pharmaceuticals?
- What is AcelRx Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for AcelRx Pharmaceuticals?
- What is AcelRx Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for AcelRx Pharmaceuticals?
What is AcelRx Pharmaceuticals annual free cash flow?
The current annual FCF of ACRX is -$17.59 M
What is the all time high annual FCF for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high annual free cash flow is -$3.77 M
What is AcelRx Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of ACRX is -$3.95 M
What is the all time high quarterly FCF for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high quarterly free cash flow is $23.53 M
What is AcelRx Pharmaceuticals TTM free cash flow?
The current TTM FCF of ACRX is -$17.59 M
What is the all time high TTM FCF for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high TTM free cash flow is -$3.55 M